Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorUniversity of Calgary
About this trial
The mechanism behind postural orthostatic tachycardia syndrome (POTS) involves many causes including a sympathetic nervous system problem. Blood gases, like carbon dioxide (CO2), have an important effect on sympathetic activation.
The purpose of this research study is to determine if higher CO2 levels have any effect in lowering heart rate and reducing POTS symptoms when upright/standing. The investigators are also searching for the ideal CO2 concentration to achieve the most effective response
Eligibility criteria
Qualifiers
Physician diagnosis of Postural Tachycardia Syndrome (POTS)
Age 18-60 years
Male and Female
Non - smokers.
Disqualifiers
Overt cause for postural tachycardia, i.e., acute dehydration
Participants with somatization or severe anxiety symptoms will be excluded
Pregnant
Inability to tolerate mask for the duration of the study
Trial design
Treatments tested in this trial
- RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
Treatment groups
26 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov